INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA – ADCT
Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC Therapeutics” or the “Company”) (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether ADC Therapeutics and certain of its officers and/or directors have engaged in securities fraud or other unlawful […]